Ringleb 7 , Igor Sibon 8 , Omid Halse 2 , Peter Heuschmann 9 , Roland Veltkamp 2,10 , Christian Enzinger 1 1 Department of Neurology, Medical University of Graz, Graz, Austria, 2 Department of Brain Sciences, Imperial College London, London, United Kingdom, 3 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece, 4 Institute de Biomedicine of Seville, IBiS/Virgen Macarena University Hospital/CSIC/University of Seville, Seville, Spain, 5 Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy, 6 Santa Maria della Misericordia Hospital, Perugia, Italy, 7 Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany, 8 Department of Neurology, CHU Bordeaux, Bordeaux University, Bordeaux, France, 9 Institute for Clinical Epidemiology and Biometry (ICE-B), University of Wrzburg, Wrzburg, Germany, 10 Department of Neurology, Alfried-Krupp Krankenhaus, Essen, Germany Background and Aims: Patients with intracerebral haemorrhage (ICH) and atrial fibrillation are at a high risk of ischemic stroke and recurrent ICH
At age 20, plasma GHK-Cu concentration averages around 200 ng/mL
This is not typical of incretin-based therapies and appears to be unique to retatrutide, possibly related to the glucagon receptor component
Similarly to insulin, amylin has similar secretion patterns with low fasting levels and marked increases following meals [29, 30]
